Drug intelligence / Profile preview

spirulina

Development stage
Phase 3
Lead developer
Ningbo University
Administration
Oral
01

Overview

Spirulina is a cyanobacterial biomass used as a **dietary supplement / nutraceutical** rather than a conventional single-molecule pharmaceutical. In the provided sources it is administered mainly orally as powder, food supplement, or diet enrichment, and has been studied clinically and preclinically in settings including HIV-associated insulin resistance, relapsing-remitting multiple sclerosis, obesity-related metabolic dysfunction, intestinal flora regulation, allergic asthma models, Parkinson's disease models, and ulcerative colitis models. Its activity is generally attributed to a mixture of bioactive constituents including phycocyanin, phycocyanobilin, carotenoids, phenolic compounds, omega-3 fatty acids, amino acids, vitamins, and antioxidant pigments, with reported antioxidant, anti-inflammatory, immunomodulatory, and metabolic effects. Because "spirulina" refers to a natural multi-component nutraceutical material rather than a precisely defined pharmaceutical active ingredient with one validated molecular target, its mechanism is best described as pleiotropic reduction of oxidative stress and inflammatory signaling rather than selective target pharmacology.

Brand names
Spirulina MAXIMA
Other names
Spirulina platensisspirulina powderspirulina supplementspirulina-enhanced diet
02

Targets

TNFA (Tumor necrosis factor alpha (soluble))NOX4 (NADPH oxidase 4)PNLIP (Pancreatic triacylglycerol lipase)

Beyond the preview

Go deeper on spirulina.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on spirulina.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call